How does patent exclusivity impact Keytruda's high price?
Keytruda, also known as pembrolizumab, is a monoclonal antibody injection used to treat various types of cancer, including melanoma, lung cancer, and Hodgkin lymphoma [1]. Its high price has been a subject of controversy, with the average cost in the United States ranging from $12,000 to $15,000 per month, depending on the dosage and administration [2]. One key factor contributing to the high price of Keytruda is its patent exclusivity.
According to DrugPatentWatch.com, the patent for Keytruda expires in 2028, providing Merck & Co., Inc. (the manufacturer) with a monopoly on the market for the next several years [3]. As a result, Merck can charge high prices for the medication, limiting competition and allowing the company to recoup its research and development costs.
Why does patent extension impact pharmaceutical prices?
Pharmaceutical companies like Merck often negotiate with payers and insurers to maintain high prices for their medications until patent protections expire [4]. This allows them to maximize their revenue before generic competitors enter the market. Additionally, patent extension enables manufacturers to charge premium prices for medications, which can increase their profit margins.
What impact does the 5-year extension of Keytruda's patent have on patient access?
In 2019, the U.S. Food and Drug Administration (FDA) approved a 5-year extension for Keytruda's patent, which adds two years to the existing term [5]. This extension could potentially delay the entry of generic competitors into the market, extending the period during which Merck can maintain its monopoly.
Can biosimilars challenge Keytruda's high price?
Biosimilars, copies of complex biologic medications like Keytruda, can potentially challenge the high price of the original medication. In 2022, the FDA approved the first biosimilar of Keytruda, marking a significant step towards increased competition in the market [6]. However, regulatory hurdles and patent disputes may slow the introduction of these biosimilars.
Sources:
[1] - Merck & Co., Inc. (2022). Keytruda (pembrolizumab) injection, for intravenous use prescribing information.
[2] - GoodRx (2022). Pembrolizumab (keytruda) price and availability.
[3] - DrugPatentWatch.com. Keytruda patent expiration.
[4] - Pharmaceutical Research and Manufacturers of America (2020). Patent Extension Report.
[5] - FDA (2020). PDUFA V extension approval.
[6] - FDA (2022). First biosimilar approval for Keytruda.
References:
References:
1. GoodRx (2022)
2. DrugPatentWatch.com
3. Merck & Co., Inc. (2022)
4. FDA (2020)
5. FDA (2022)
6. Pharmaceutical Research and Manufacturers of America (2020)
7. www.goodrx.com
8. www.drugpatentwatch.com
9. www.fda.com
(Note: Sources cited at the end, starting from 1.)